ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease

Honig, L. S., Barakos, J., Dhadda, S., Kanekiyo, M., Reyderman, L., Irizarry, M., Kramer, L. D., Swanson, C. J., & Sabbagh, M. (2023). ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer’s disease. Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 9(1). Portico. https://doi.org/10.1002/trc2.12377
Authors:
Lawrence S Honig
Jerome Barakos
Shobha Dhadda
Michio Kanekiyo
Larisa Reyderman
Michael Irizarry
Lynn D Kramer
Chad J Swanson
Marwan Sabbagh
Affiliated Authors:
Lawrence S Honig
Author Keywords:
alzheimer's disease
anti-amyloid
aria
exposure response modeling
lecanemab
anti‐amyloid
Publication Type:
Article
Unique ID:
10.1002/trc2.12377
PMID:
Publication Date:
Data Source:
PubMed

Record Created: